NICE is indeed the standard investors should be watching
If that's your belief, then it's hard to see the logic for investing in biotech at all. Do you think NICE will pay for the new HCV drugs? Or Vertex's new cystic fibrosis drug? Or even Amarin's EPA pill at the lower end of the pricing spectrum?